Affiliation
Department of Radiotherapy, Christie Hospital, Holt Radium Institute, Manchester, England.Issue Date
1992
Metadata
Show full item recordAbstract
A clinical trial was carried out at The Christie Hospital, Manchester, England, between November 1976 and June 1982. Following surgery, patients with clinical stage T1-T3a, N1-N2b, M0 tumors were randomly allocated in the following way: premenopausal women to either tamoxifen 20 mg/day for 1 year or to an irradiation-induced menopause; postmenopausal women to either tamoxifen for 1 year or no further treatment (controls). In the node-negative subgroup, an analysis at a median follow-up of 10 years shows no statistically significant difference in overall or disease-free survival between tamoxifen-treated patients and irradiation-induced menopause and control patients. Side effects were few, and compliance was excellent. There was no significant increase of second primary tumors in target endocrine organs in the tamoxifen-treated patients. For the whole series of 961 patients, a log-rank analysis of events, allowing for node status, still shows a statistically significant benefit for tamoxifen-treated patients (P = .04).Citation
The Christie Hospital adjuvant tamoxifen trial. 1992 (11):121-5 J. Natl. Cancer Inst MonographsJournal
Journal of the National Cancer Institute MonographsPubMed ID
1627418Type
ArticleLanguage
enISSN
1052-6773Collections
Related articles
- Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
- Authors: Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P
- Issue date: 1995 Feb
- Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
- Authors: Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group
- Issue date: 2007 Jan
- Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
- Authors: International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD
- Issue date: 2006 Mar 20
- A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group.
- Authors: Dalberg K, Johansson H, Johansson U, Rutqvist LE
- Issue date: 1998 Jun 1
- Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
- Authors: Freedman GM, Anderson P, Li T, Ross E, Swaby R, Goldstein L
- Issue date: 2006 Dec 1